PeptiMed Signs Agreement With National Cancer Institute to Assess Safety of HelpTM Drug Delivery Nanoparticle Formulations
6/23/2014 11:43:13 AM
MADISON, Wisc.--(BUSINESS WIRE)--PeptiMed announced today that under a Material Transfer Agreement it will collaborate with the National Cancer Institute’s (NCI) Nanotechnology Characterization Laboratory (NCL), located at the Frederick National Laboratory of Cancer Research in Frederick, MD. Under the terms of the Agreement, PeptiMed will provide the NCL with nanocomplex consisting of its proprietary siRNA and patented elastin-like polypeptides (ELPs), and NCL personnel will measure material properties indicative of safety and efficacy for potential future dosing in the clinic.
Help employers find you! Check out all the jobs and post your resume.
comments powered by